Thursday, June 20, 2024

Predictive Oncology gains, to present positive results from a retrospective study

Must read

Scientists working in the laboratory


  • Predictive Oncology (NASDAQ:POAI) shares jumped in pre-market trade on Tuesday, after it said positive results from a retrospective study recently completed in collaboration with UPMC Magee-Womens Hospital, will be presented at the American Society of Clinical Oncology Annual Meeting to be held between May 31-June 4.
  • POAI +50.37% premarket to $2.36.
  • The purpose of the study was to determine if Predictive Oncology (POAI) could leverage its artificial intelligence and other capabilities to develop machine learning models that could more accurately predict both short-term (two-year) and long-term (five-year) survival outcomes among ovarian cancer patients.
  • “The results of this important study strongly support continued development of such ML models and subsequent incorporation into daily clinical practice,” the company said.
  • Arlette Uihlein, MD, Senior Vice President, Translational Medicine and Drug Discovery, and Medical Director, Predictive Oncology said, “We believe these results highlight the potential of AI and machine learning to not only accelerate early oncology drug discovery, but to assist with the clinical management of cancer patients in real-time, thereby improving survival outcomes.”
  • Source: Press Release

More articles

Latest article